Seedhouse Claire, Russell Nigel
Department of Academic Haematology, University of Nottingham, Nottingham University Hospitals, Nottingham, UK.
Br J Haematol. 2007 Jun;137(6):513-29. doi: 10.1111/j.1365-2141.2007.06613.x.
Treatment-related acute myeloid leukaemia (t-AML) is a devastating complication following exposure to the cytotoxic and genotoxic agents used to treat a primary malignancy. Whilst the incidence of t-AML is rising, it still only occurs in a minority of patients who have received chemotherapy and/or radiotherapy treatment and hence it is important to identify factors that may confer susceptibility to the development of the condition. This paper reviews the literature and discusses the advances and limitations in our understanding of susceptibility factors to t-AML. In particular, it concentrates upon genetic polymorphisms in detoxification genes and in genes belonging to the major DNA repair pathways. This review also considers more novel susceptibility factors, such as those proposed to determine stem cell number. Increased understanding of t-AML susceptibility may enable steps to be taken to prevent its development and increase the effectiveness of treatment of the disease.
治疗相关的急性髓系白血病（t-AML）是接触用于治疗原发性恶性肿瘤的细胞毒性和基因毒性药物后出现的一种毁灭性并发症。虽然t-AML的发病率在上升，但它仍仅发生在少数接受过化疗和/或放疗的患者中，因此识别可能使个体易患该病的因素很重要。本文回顾了相关文献，并讨论了我们在理解t-AML易感性因素方面的进展和局限性。特别关注解毒基因和主要DNA修复途径相关基因中的遗传多态性。本综述还考虑了更新颖的易感性因素，比如那些被认为可决定干细胞数量的因素。对t-AML易感性的深入了解可能有助于采取措施预防其发生，并提高该病的治疗效果。
